There is a pattern in biotech product launches that we have decided not to follow. The pattern goes like this: develop in isolation, polish the marketing, launch with a press release, and hope the product meets the market. It works sometimes. When it does not, the reasons are usually the same—the product was built for a laboratory that exists in the founder’s imagination, not in the real world.

DNA ME is taking a different approach. We are launching two closed beta programs simultaneously—Pioneer Access for individual researchers and the Preferred Research Lab Partner Program for institutions—not because our platform is unfinished, but because we believe the best products are shaped by the people who use them.

The technology works. We have processed samples, validated panels, and filed a patent (PCT/EP2024/083862). What we have not done—and cannot do alone—is test our workflow against the full diversity of real research conditions. A microbiome lab processes samples differently than an eDNA monitoring station. A veterinary diagnostic lab has different throughput demands than a plant pathology group. We need to see how our single-chemistry, any-panel platform performs in each of these contexts, and we need to hear what works and what requires adjustment.

This is not performative transparency. We are not sharing our roadmap for attention. We are building in public because it produces a better product, faster. Every beta participant is a collaborator whose feedback directly shapes what DNA ME becomes. Their experience becomes our evidence—the case studies, the testimonials, and eventually the publications that demonstrate what the platform can do in hands other than our own.

We believe research should not wait for logistics. But we also believe products should not launch without the input of the people they serve. These beta programs are how we reconcile those two beliefs. If you are a researcher who wants faster, more flexible sequencing, or a laboratory considering a simpler workflow, we invite you to be part of what we are building. Not as a customer. As a collaborator.

Same kit. Any panel. Results you can publish. And shaped by scientists, together.